Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females

Vaccination anti-HPV et risque de maladies auto-immunes : étude de cohorte française

(2016) S. Miranda et al.   REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE

An Overview of Quadrivalent Human Papillomavirus Vaccine Safety

(2015) Michelle Vichnin et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial

(2015) Orestis A Panagiotou et al.   BMJ-British Medical Journal

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial

(2015) Ting Fan Leung et al.   Human Vaccines & Immunotherapeutics

Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial

(2015) Orestis A Panagiotou et al.   BMJ-British Medical Journal

Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review

(2014) Ana Katherine Gonçalves et al.   Brazilian Journal of Infectious Diseases

Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women

(2014) E. M. Kojic et al.   CLINICAL INFECTIOUS DISEASES

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

(2014) S Rachel Skinner et al.   LANCET

Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

(2014) Maria-Genalin Angelo et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials

(2014) Pierre Van Damme et al.   VACCINE

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years

(2014) Fengcai Zhu et al.   Human Vaccines & Immunotherapeutics

Comparison of the Immunogenicity and Reactogenicity of Cervarix and Gardasil Human Papillomavirus Vaccines in HIV-Infected Adults: A Randomized, Double-Blind Clinical Trial

(2013) L. Toft et al.   JOURNAL OF INFECTIOUS DISEASES

A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls

(2013) Eve Draper et al.   PLoS One

A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18–26 years

(2013) E. Anthony S. Nelson et al.   VACCINE

Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study

(2013) L. Arnheim-Dahlstrom et al.   BMJ-British Medical Journal

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women

(2012) Papa Salif Sow et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized Trial of the Immunogenicity and Safety of the Hepatitis B Vaccine Given in an Accelerated Schedule Coadministered with the Human Papillomavirus Type 16/18 AS04-Adjuvanted Cervical Cancer Vaccine

(2011) Geert Leroux-Roels et al.   Clinical and Vaccine Immunology

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

(2011) Barbara Romanowski et al.   Human vaccines & immunotherapeutics

Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls

(2011) Court Pedersen et al.   JOURNAL OF ADOLESCENT HEALTH

Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women

(2011) Seung Cheol Kim et al.   Journal of Gynecologic Oncology

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-adjuvanted Vaccine Coadministered With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and/or Meningococcal Conjugate Vaccine to Healthy Girls 11 to 18 Years of Age

(2011) Cosette M. Wheeler et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls

(2011) Channa E. Schmeink et al.   VACCINE

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

(2010) Dominique Descamps et al.   Human vaccines & immunotherapeutics

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis–inactivated Poliovirus Vaccine to Girls and Young Women

(2010) José Garcia-Sicilia et al.   JOURNAL OF ADOLESCENT HEALTH

Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years

(2010) Young-Jae Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines

(2010) A. Arguedas et al.   VACCINE

Public knowledge and attitudes towards Human Papilloma Virus (HPV) vaccination

(2008) Charlotte Devereaux Walsh et al.   BMC PUBLIC HEALTH

Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years

(2008) Tiina Petäjä et al.   JOURNAL OF ADOLESCENT HEALTH